Moore AE - Search Results

1

Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis.

Moore AE, Blake GM, Taylor KA, Ruff VA, Rana AE, Wan X, Fogelman I. Moore AE, et al. Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):326-36. doi: 10.1007/s00259-011-1974-y. Epub 2011 Nov 5. Eur J Nucl Med Mol Imaging. 2012. PMID: 22057627 Free PMC article.

2

Conventional measurements of GFR using 51Cr-EDTA overestimate true renal clearance by 10 percent.

Moore AE, Park-Holohan SJ, Blake GM, Fogelman I. Moore AE, et al. Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):4-8. doi: 10.1007/s00259-002-1007-y. Epub 2002 Oct 26. Eur J Nucl Med Mol Imaging. 2003. PMID: 12483403 Clinical Trial.

3

Validation of ultrafiltration as a method of measuring free 99mTc-MDP.

Moore AE, Hain SF, Blake GM, Fogelman I. Moore AE, et al. J Nucl Med. 2003 Jun;44(6):891-7. J Nucl Med. 2003. PMID: 12791815 Free article. Clinical Trial.

4

A direct in vivo measurement of 99mTc-methylene diphosphonate protein binding.

Blake GM, Moore AE, Park-Holohan SJ, Fogelman I. Blake GM, et al. Among authors: moore ae. Nucl Med Commun. 2003 Jul;24(7):829-35. doi: 10.1097/00006231-200307000-00014. Nucl Med Commun. 2003. PMID: 12813203 Clinical Trial.

5

Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearance.

Moore AE, Blake GM, Fogelman I. Moore AE, et al. J Nucl Med. 2006 Apr;47(4):581-6. J Nucl Med. 2006. PMID: 16595490 Free article. Clinical Trial.

6

A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentration.

Moore AE, Blake GM, Fogelman I. Moore AE, et al. Nucl Med Commun. 2007 Mar;28(3):187-92. doi: 10.1097/MNM.0b013e3280143a0a. Nucl Med Commun. 2007. PMID: 17264777

7

Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling.

Moore AE, Blake GM, Fogelman I. Moore AE, et al. J Nucl Med. 2008 Mar;49(3):375-82. doi: 10.2967/jnumed.107.048595. Epub 2008 Feb 20. J Nucl Med. 2008. PMID: 18287266 Free article.

8

Quantitative studies of bone using (99m)Tc-methylene diphosphonate skeletal plasma clearance.

Blake GM, Moore AE, Fogelman I. Blake GM, et al. Among authors: moore ae. Semin Nucl Med. 2009 Nov;39(6):369-79. doi: 10.1053/j.semnuclmed.2009.05.001. Semin Nucl Med. 2009. PMID: 19801217 Review.

9

Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment.

Moore AE, Blake GM, Taylor KA, Rana AE, Wong M, Chen P, Fogelman I. Moore AE, et al. J Bone Miner Res. 2010 May;25(5):960-7. doi: 10.1359/jbmr.091108. J Bone Miner Res. 2010. PMID: 19929434 Free article. Clinical Trial.

10

Differential effects of teriparatide on regional bone formation using (18)F-fluoride positron emission tomography.

Frost ML, Siddique M, Blake GM, Moore AE, Schleyer PJ, Dunn JT, Somer EJ, Marsden PK, Eastell R, Fogelman I. Frost ML, et al. Among authors: moore ae. J Bone Miner Res. 2011 May;26(5):1002-11. doi: 10.1002/jbmr.305. J Bone Miner Res. 2011. PMID: 21542003 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters